These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2964327)

  • 1. Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
    Scott AR; Tattersall RB
    Diabet Med; 1988 Jan; 5(1):42-6. PubMed ID: 2964327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
    Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
    Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
    Johnson AB; Taylor R
    Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
    Johnston PS; Coniff RF; Hoogwerf BJ; Santiago JV; Pi-Sunyer FX; Krol A
    Diabetes Care; 1994 Jan; 17(1):20-9. PubMed ID: 8112185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
    Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
    Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
    Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
    Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
    Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
    J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
    Heinz G; Komjati M; Korn A; Waldhäusl W
    Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
    Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD
    Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. alpha-Glucosidase inhibition by miglitol in NIDDM patients.
    Kingma PJ; Menheere PP; Sels JP; Nieuwenhuijzen Kruseman AC
    Diabetes Care; 1992 Apr; 15(4):478-83. PubMed ID: 1499461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
    Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
    Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
    Holman RR; Steemson J; Turner RC
    Diabetes Res; 1991 Dec; 18(4):149-53. PubMed ID: 1842749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
    Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
    Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
    Pagano G; Marena S; Corgiat-Mansin L; Cravero F; Giorda C; Bozza M; Rossi CM
    Diabete Metab; 1995 Jun; 21(3):162-7. PubMed ID: 7556806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Delayed absorption of carbohydrates in the therapy of Type II diabetes: comparison between dietary (Muesli) and pharmacological (Alpha-glucosidase inhibition) modification].
    Willms B; Lübke D; Ahrens K; Arends J
    Schweiz Med Wochenschr; 1991 Sep; 121(38):1379-82. PubMed ID: 1656521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
    Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
    Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
    Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase.
    Joubert PH; Foukaridis GN; Bopape ML
    Eur J Clin Pharmacol; 1987; 31(6):723-4. PubMed ID: 3549325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
    Van Gaal L; Maislos M; Schernthaner G; Rybka J; Segal P
    Diabetes Obes Metab; 2001 Oct; 3(5):326-31. PubMed ID: 11703422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man.
    Lembcke B; Fölsch UR; Gatzemeier W; Ebert R; Siegel E; Creutzfeldt W
    Pharmacology; 1991; 43(6):318-28. PubMed ID: 1784628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.